title: [Not Available].
abstract: Specificity of antifungals use in paediatric patients is linked to mycoses epidemiology in this population. Pharmacokinetics vary with patient age. Although studies are in progress, pharmacokinetic data in children are limited in number for most antifungals. Among antifungal agents, those approved in France for use in children are rare. Adverse event frequency can differ in children, as compared to frequency in adults, and drug interaction should be a major worry. Relative interest and cost of available forms in the paediatric population in not always taken into account. For each different situation, an optimal strategy of antifungals use in children should be determined.
authors.affiliation: Service d'Hémato-Oncologie Pédiatrique, Hôpital Trousseau, Paris, France. Electronic address: marie-dominique.tabone@trs.aphp.fr.
authors.forename: Marie-Dominique
authors.initials: MD
authors.lastname: Tabone
authors.affiliation: Pharmacie, Hôpital Trousseau, Paris, France.
authors.forename: Nathalie Le
authors.initials: NL
authors.lastname: Guyader
authors.affiliation: Service d'Hémato-Oncologie Pédiatrique, Hôpital Trousseau, Paris, France.
authors.forename: Guy
authors.initials: G
authors.lastname: Leverger
keywords: antifongiques; antifungals; approval; autorisation de mise sur le marché; children; cost; coût; infant; neonates; pédiatrie